Associated Papers
Comprehensive resistance profiling of chronic myeloid leukaemia associated ABL1 variants against five tyrosine kinase inhibitors using prime editing.
Jung Y et al.
Nature Biomedical Engineering, 2025
Innovative rapid screening for complex BCR-ABL1 kinase domain mutations in TKI-treated leukaemia patients.
Lan Y et al.
British Journal of Cancer, 2025
Significance of Somatic Mutation Profiling in CML Beyond BCR-ABL: A Retrospective Study of the Indian Population.
Chaudhary P et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion, 2025
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy.
Innes AJ et al.
Leukemia, 2024
Cytogenetics and genomics in CML and other myeloproliferative neoplasms.
Kreipe HH et al.
Best Practice & Research. Clinical Haematology, 2024
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
Sánchez R et al.
Scientific Reports, 2022
Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing.
Easwar A et al.
Life (basel, Switzerland), 2021
ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors.
Shojaei M et al.
Laboratory Medicine, 2021
Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors.
Li J et al.
Journal of Translational Medicine, 2020
Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand.
Limsuwanachot N et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2020
T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
Ting S et al.
Annals of Hematology, 2020
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
Soverini S et al.
Blood, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways.
Magistroni V et al.
Haematologica, 2019
Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
Etienne G et al.
Cancer Medicine, 2019
Mutations Associated with Imatinib Mesylate Resistance - Review.
Linev AJ et al.
Folia Medica, 2018
Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias.
Schmitt MW et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Comparison of Frequency and Sensitivity of BCR-ABL1 Kinase Domain Mutations in Asian and White Patients With Imatinib-resistant Chronic-Phase Chronic Myeloid Leukemia.
Kim H et al.
Clinical Lymphoma, Myeloma & Leukemia, 2018
B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy.
Zhang X et al.
Oncotarget, 2017
Imatinib resistance in chronic myeloid leukemia due to a rare mutation.
Balasubramanian P et al.
Leukemia & Lymphoma, 2017
Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.
Tsubaki M et al.
Oncotarget, 2017
Treatment of chronic myelogenous leukemia.
Kujak C et al.
American Journal of Health-system Pharmacy : Ajhp : Official Journal of the American Society of Health-system Pharmacists, 2016
Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing.
Szankasi P et al.
Annals of Hematology, 2016
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T et al.
Nature, 2015
Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.
Ai J et al.
Therapeutic Advances in Hematology, 2014
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
Soverini S et al.
Leukemia Research, 2014
Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group.
Itonaga H et al.
Leukemia Research, 2014
Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.
Shih LY et al.
Leukemia Research, 2013
Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S et al.
American Journal of Hematology, 2012
Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.
Razga F et al.
Molecular Diagnosis & Therapy, 2012
Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.
Parker WT et al.
Blood, 2012
Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.
Parker WT et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2011
Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.
Quintás-Cardama A et al.
Haematologica, 2011
BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay.
Ono T et al.
Leukemia Research, 2011
Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Yeh CH et al.
Cancer Biomarkers : Section a of Disease Markers, 2010
Mutations in the breakpoint cluster region-Abelson murine leukemia 1 gene in Brazilian patients with chronic myeloid leukemia.
Costa HZ et al.
Hematology, Transfusion and Cell Therapy, 0